These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 9526191)

  • 1. Does the efficacy of BCG decline with time since vaccination?
    Sterne JA; Rodrigues LC; Guedes IN
    Int J Tuberc Lung Dis; 1998 Mar; 2(3):200-7. PubMed ID: 9526191
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The efficacy of bacillus Calmette-Guérin vaccination of newborns and infants in the prevention of tuberculosis: meta-analyses of the published literature.
    Colditz GA; Berkey CS; Mosteller F; Brewer TF; Wilson ME; Burdick E; Fineberg HV
    Pediatrics; 1995 Jul; 96(1 Pt 1):29-35. PubMed ID: 7596718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Novel vaccines against M. tuberculosis].
    Okada M
    Kekkaku; 2006 Dec; 81(12):745-51. PubMed ID: 17240920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. What does tuberculin reactivity after bacille Calmette-Guérin vaccination tell us?
    Menzies D
    Clin Infect Dis; 2000 Sep; 31 Suppl 3():S71-4. PubMed ID: 11010826
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Where do we stand with BCG vaccination programme in Japan?].
    Mori T
    Kekkaku; 2001 Apr; 76(4):385-97. PubMed ID: 11398330
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neonatal BCG protection against tuberculosis lasts for 20 years in Brazil.
    Barreto ML; Cunha SS; Pereira SM; Genser B; Hijjar MA; Yury Ichihara M; de Brito SC; Dourado I; Cruz A; Santa'Ana C; Rodrigues LC
    Int J Tuberc Lung Dis; 2005 Oct; 9(10):1171-3. PubMed ID: 16229231
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preventing tuberculosis with bacillus Calmette-Guérin vaccine: a meta-analysis of the literature.
    Brewer TF
    Clin Infect Dis; 2000 Sep; 31 Suppl 3():S64-7. PubMed ID: 11010824
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An analysis of some hypotheses related to the Chingelput bacille Calmette-Guérin trial.
    Smith D; Wiegeshaus E; Balasubramanian V
    Clin Infect Dis; 2000 Sep; 31 Suppl 3():S77-80. PubMed ID: 11010828
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bacille Calmette Guérin vaccination in pre-term infants.
    Sedaghatian MR; Hashem F; Moshaddeque Hossain M
    Int J Tuberc Lung Dis; 1998 Aug; 2(8):679-82. PubMed ID: 9712284
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The cytokine response to bacille Calmette Guérin vaccination in South India.
    Das SD; Narayanan PR; Kolappan C; Colston MJ
    Int J Tuberc Lung Dis; 1998 Oct; 2(10):836-43. PubMed ID: 9783532
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors influencing the protective efficacy of a BCG homologous prime-boost vaccination regime against tuberculosis.
    Griffin JF; Mackintosh CG; Rodgers CR
    Vaccine; 2006 Feb; 24(6):835-45. PubMed ID: 16098638
    [TBL] [Abstract][Full Text] [Related]  

  • 12. No adverse events after simultaneous administration of 50 000 IU vitamin A and Bacille Calmette-Guerin vaccination to normal-birth-weight newborns in Guinea-Bissau.
    Nante JE; Diness BR; Ravn H; Roth A; Aaby P; Benn CS
    Eur J Clin Nutr; 2008 Jul; 62(7):842-8. PubMed ID: 17538544
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evidence of protective effect of BCG vaccination in persons at low risk of tuberculosis in Nordic countries.
    Brantsaeter AB; Romanus V; Andersen PH; Heldal E
    Int J Tuberc Lung Dis; 2009 Apr; 13(4):440-5. PubMed ID: 19335948
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PPD induced in vitro interferon gamma production is not a reliable correlate of protection against Mycobacterium tuberculosis.
    Elias D; Akuffo H; Britton S
    Trans R Soc Trop Med Hyg; 2005 May; 99(5):363-8. PubMed ID: 15780343
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systematic review and meta-analysis of the current evidence on the duration of protection by bacillus Calmette-Guérin vaccination against tuberculosis.
    Abubakar I; Pimpin L; Ariti C; Beynon R; Mangtani P; Sterne JA; Fine PE; Smith PG; Lipman M; Elliman D; Watson JM; Drumright LN; Whiting PF; Vynnycky E; Rodrigues LC
    Health Technol Assess; 2013 Sep; 17(37):1-372, v-vi. PubMed ID: 24021245
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical inquiries. How should we manage a patient with a positive PPD and prior BCG vaccination?
    Rowland K; Guthmann R; Jamieson B; Malloy D
    J Fam Pract; 2006 Aug; 55(8):718-20. PubMed ID: 16882448
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BCG and prospects for new vaccines against tuberculosis.
    Ortona L; De Luca A
    Rays; 1998; 23(1):225-30. PubMed ID: 9673148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of BCG vaccine strain on the immune response and protection against tuberculosis.
    Ritz N; Hanekom WA; Robins-Browne R; Britton WJ; Curtis N
    FEMS Microbiol Rev; 2008 Aug; 32(5):821-41. PubMed ID: 18616602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of number of BCG vaccination on tuberculin induration size.
    Gundogdu Z; Aydogan M; Arisoy ES; Gokalp AS
    J Paediatr Child Health; 2007 Jun; 43(6):476-9. PubMed ID: 17535179
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mucosal bacille calmette-Guérin vaccination of humans inhibits delayed-type hypersensitivity to purified protein derivative but induces mycobacteria-specific interferon-gamma responses.
    Hoft DF; Brown RM; Belshe RB
    Clin Infect Dis; 2000 Jun; 30 Suppl 3():S217-22. PubMed ID: 10875787
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.